The effect of sitagliptin on serum PAI-1 concentration in type 2 diabetic patient.

Trial Profile

The effect of sitagliptin on serum PAI-1 concentration in type 2 diabetic patient.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 May 2016

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Jun 2012 Actual end date (Mar 2012) added as reported by University Hospital Medical Information Network - Japan record.
    • 03 Jun 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
    • 03 Jun 2011 Planned initiation date (Dec 2012) added as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top